期刊文献+

CISH、IHC联合检测胃腺癌EGFR、HER2基因状态及其临床意义 被引量:2

Combined detection of EGFR and HER2 in gastric adenocarcinoma by CISH and IHC
暂未订购
导出
摘要 目的比较显色原位杂交(CISH)与免疫组织化学(IHC)检测胃腺癌表皮生长因子(EGFR)及表皮生长因子受体2(HER2)的基因状态。方法 CISH及IHC检测85例胃腺癌组织EGFR、HER2基因扩增及蛋白表达。结果 EGFR蛋白表达阳性29例,其中表达(3+)的4例中,4例基因扩增;表达(2+)的11例中,8例基因扩增;表达(1+)的14例中,1例基因扩增。HER2蛋白表达阳性13例,其中表达(3+)的4例中,4例基因扩增;表达(2+)的6例中,5例基因扩增;表达(1+)的3例中,无基因扩增。EGFR、HER2蛋白表达及基因扩增无相关性。结论 IHC检测蛋白表达仅(3+)与CISH检测基因扩增有较好一致性,CISH检测基因状态有较好特异性。 Objective To compare the expressions of epidermal growth factor(EGFR) and human epidermal growth factor receptor 2(HER2) in gastric adenocarcinoma by chromogenic in situ hybridization(CISH) and immunohisto- chemistry (IHC), respectively. Methods EGFR and HER2 expressions of 85 cases with gastric adenocarcinomas were detected by CISH and IHC. Results Among 29 patients with positive EGFR, four cases with (3+) showed gene amplification; eight of 1 lcases with (2+) showed gene amplification; only one of the 14 cases with (1+) showed gene amplification. Among 13 patients with positive HER2, four cases with (3+) showed gene amplification; five of six cases with (2+) showed gene amplification; three cases with (1+) failed to show gene amplification. There was no correlation between gene amplification and EGFR or HER2. Conclusions Cases with (3+) oflHC is consistency with CISH preferably, and CISH has a high specificity in predicting gene status.
机构地区 义乌市中心医院
出处 《现代实用医学》 2012年第1期26-28,F0003,共4页 Modern Practical Medicine
基金 浙江省义乌市科技局资助项目(2008-3-07)
关键词 显色原位杂交 免疫组织化学 胃腺肿瘤 CISH IHC gastric adenocarcinoma EGFR HER2
  • 相关文献

参考文献6

  • 1Kim MA,Jung EJ,Lee HS,et al.Evaluation of HER-2/neu genestatus in gastric carcinoma using immunohistochemistry,fluorescencein situ hybridization,and real-time quantitative polymerase chainreaction[J].Hum Pathol,2007,38(9):1386-1393.
  • 2Dandachi N,Dietze O,Hauser-Kronberger C.Evaluation of the cli-nical significance of HER-2/neu amplification by chromogenic insitu hybridisation in patients with primary breast cancer[J].Anti-cancer Res,2004,24(4):2401-2406.
  • 3Hauser-Kronberger C,Dandachi N.Comparison of chromogenic insitu hybridization with other methodologies for HER-2/neu statusassessment in breast cancer[J].J Mol Histol,2004,35(6):647-653.
  • 4Wixom CR,Albers EA,Weidner N.HER-2/neu amplification:cor-relation of chromogenic in situ hybridization with immunohisto-chemistry and fluorescence in situ hybridization[J].Appl Immuno-histochem Mol Morphol,2004,12(3):248-251.
  • 5Tanner M,Hollmén M,Junttila TT,et al.Amplification of HER-2/neu in gastric carcinoma:association with Topoisomerase IIalphagene amplification,intestinal type,poor prognosis and sensitivity totrastuzumab[J].Ann Oncol,2005,16(2):273-278.
  • 6Park DI,Yun JW,Park JH,et al.HER-2/neu amplification is an in-dependent prognostic factor in gastric cancer[J].Dig Dis Sci,2006,51(8):1371-1379.

同被引文献14

  • 1Huang D,Lu N,Fan Q,et al.HER-2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories:Chinese results of the HER-EAGLE study[J].Plo S One,2013,8(11):e80290.
  • 2De SN,Schulz L,Paterson A,et al.Molecular effects of lapatinib in the treatment of HER-2 overexpressing oesophago-gastric adenocarcinoma[J].Brit Cancer,2015,113(9):1305-1312.
  • 3PARK SR,PARK YS,RYU MH,et al.Extra-gain of HER-2-positive cases through HER-2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER-2-negative primary tumours:Results of GASTric cancer HER-2 reassessment study 1(GASTHER-1)[J].Euro J Cancer,2016,53:42-50.
  • 4Jomrich G,Schoppmann SF.Targeting HER-2 and angiogenesis in gastric cancer[J].Expert Revi Anticanc,2015,16(1):1-54.
  • 5Segami K,Sato T,Kawabe T,et al.A case of HER-2 positive advanced gastric cancer responding to capecitabine+cisplatin+trastuzumab chemotherapy[J].Gan to Kagaku Ryoho Cancer&Chemotherapy,2015,42(10):1295-1297.
  • 6Ieni A,Barresi V,Rigoli L,et al.HER-2 Status in Premalignant,Early,and Advanced Neoplastic Lesions of the Stomach[J].Disease Markers,2015,2015:234851.
  • 7Meulendijks D,Beerepoot LV,Boot H,et al.Trastuzumab and bevacizumab combined with docetaxel,oxaliplatin and capecitabine as firstline treatment of advanced HER-2-positive gastric cancer:a multicenter phase II study[J].Investigational New Drugs,2016,34:1-10.
  • 8Chao WR,Lee MY,Ruan A,et al.Assessment of HER-2 Status using immunohistochemistry(IHC)and fluorescence in situ hybridization(fish)techniques in mucinous epithelial ovarian cancer:a comprehensive comparison between To GA biopsy method and To GA surgical specimen method[J].Plos One,2015,10(1):29-36.
  • 9Cappellesso R,Fassan M,Hanspeter E,et al.HER-2 status in gastroesophageal cancer:a tissue microarray study of 1040 cases[J].Human Pathol,2015,46(5):665-672.
  • 10胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557. 被引量:103

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部